The regulation of medical devices within the European Union has undergone a significant transformation with the replacement of the Medical Device Directive (MDD 93/42/EEC) and the Active Implantable Medical Device Directive (AIMDD 90/385/EEC) by the Medical Device Regulation (MDR, EU 2017/745). While the MDD provided a foundational framework for device approval and market access, it gradually became outdated due to rapid technological advancements, cross-border trade, and high-profile safety incidents, such as the PIP breast implant scandal. The MDR was introduced to address these shortcomings, placing a stronger emphasis on patient safety, transparency, clinical evidence, and post-market surveillance. With its legally binding and directly applicable nature, the MDR has redefined the responsibilities of all economic operators and increased the regulatory burden on manufacturers and notified bodies alike. This article presents an analytical comparison between the MDD and MDR frameworks, examines the strategic implications of the MDR for manufacturers and certification processes, and discusses best practices for achieving compliance in a highly regulated and evolving healthcare market.

From MDD to MDR: Expanding Scope, Stricter Oversight, and Greater Transparency

The Medical Device Directive (MDD 93/42/EEC) served as the main framework for regulating medical devices in Europe for many years. However, as a directive, it had to be transposed into national laws by each Member State, which caused differences and inconsistencies in how it was implemented. The Medical Device Regulation (MDR EU 2017/745), on the other hand, is directly applicable, meaning it is uniformly enforced across all EU countries. Beyond its legal status, MDR also introduces significant structural changes. Its scope has been expanded to include aesthetic products, stand-alone software, and nanomaterials, while classification rules have become more detailed and risk-based. Clinical evaluation requirements have been strengthened: under the MDD, manufacturers often relied on equivalence with similar devices, but MDR now requires robust clinical data to demonstrate safety and performance. Post-market surveillance has shifted from a largely voluntary process to a mandatory, systematic one, including post-market clinical follow-up (PMCF) plans and periodic safety update reports (PSURs). Traceability has also been improved through the introduction of a Unique Device Identification (UDI) system and the creation of the European Database on Medical Devices (EUDAMED), which enhances transparency. Additionally, MDR clearly defines the roles and responsibilities of all economic operators—manufacturers, importers, distributors, and authorised representatives—while giving notified bodies greater authority and stricter oversight responsibilities. In summary, MDR is not just a new legal instrument but a broader and more stringent regulatory framework compared to the MDD, transforming how medical devices are assessed, monitored, and made available on the European market.

New Obligations for Manufacturers under MDR 

The MDR significantly increases manufacturers’ responsibilities compared to the MDD, with a strong focus on clinical evaluation and post-market surveillance. Manufacturers are now required to demonstrate the safety and performance of their devices not only through technical documentation but also with robust clinical evidence. In this context, clinical investigations designed and conducted according to the intended purpose of the device have become essential. The MDR has limited the use of literature-based equivalence, making it mandatory—particularly for high-risk devices—that clinical data be generated directly from the device itself.

To obtain CE certification, a device must undergo an objective, transparent, and academically sound evaluation covering its performance, safety, and risk management. This includes the validity of clinical data, the reliability of statistical analyses, and a scientifically grounded assessment of the benefit–risk balance. Furthermore, manufacturers are required to maintain evidence after the device enters the market by implementing Post-Market Clinical Follow-up (PMCF) plans and submitting Periodic Safety Update Reports (PSURs) regularly.

In essence, the MDR obliges manufacturers not only to design and place devices on the market but also to continuously demonstrate their safety and effectiveness throughout the entire product lifecycle. This approach both enhances patient safety and strengthens trust in medical devices within the European market.

The MDR requires manufacturers to demonstrate the performance and safety of their devices not only through technical documentation but also with scientifically valid evidence. In this context, clinical studies have become a fundamental tool to prove that a device is genuinely safe and effective for its intended purpose. Meeting performance and safety requirements with methodologically sound clinical research and statistically meaningful results is no longer just an academic expectation but a legal obligation. The MDR does not consider theoretical conformity sufficient; instead, it adopts an approach that prioritises real-world clinical effectiveness and patient safety. For this reason, it is essential that manufacturers clearly understand the purpose of the regulation and carefully address its requirements during the certification process. It is essential to remember that the MDR has been designed primarily to protect human health. Introducing a product to the market without fully meeting safety and performance requirements can result in risks being discovered during actual use, potentially leading to legal consequences and compensation liabilities. Therefore, both manufacturers and healthcare professionals should approach MDR from this perspective.

The Importance of EUDAMED and the UDI System

With the implementation of MDR, the European Union has introduced two key digital tools to improve the transparency, traceability, and safety of medical devices: EUDAMED and the UDI system.

EUDAMED (European Database on Medical Devices) is a centralised database that collects information on devices, manufacturers, clinical data, and post-market surveillance activities. It allows regulatory authorities and healthcare professionals to access up-to-date information while also ensuring greater transparency for the public.

The UDI (Unique Device Identification) system requires each medical device to have a unique identifier. This guarantees traceability throughout the entire supply chain, from manufacturing to patient use. The system enhances the efficiency of recall procedures and offers notable benefits for hospital inventory management.

Together, EUDAMED and UDI demonstrate MDR’s focus not only on device safety and performance but also on transparency, data management, and patient trust. These tools enhance the reliability and accountability of medical devices circulating in the European market.

Conclusion

The shift from MDD to MDR is not just a legal update; it represents a structural change that transforms the entire European medical device industry. MDR requires manufacturers to prove device safety and performance with strong clinical evidence, while post-market surveillance and transparency measures ensure ongoing monitoring throughout the product's lifecycle. Although this leads to higher costs, increased documentation, and ongoing compliance requirements for manufacturers, it ultimately enhances patient safety and fosters trust in medical devices within the European market. Essentially, MDR makes sure that medical devices are not only evaluated when they are first introduced but are also continuously assessed throughout their entire lifespan, promoting a culture of quality, safety, and transparency in healthcare systems.

--AHHM Issue 70--